Journal
CLINICAL CANCER RESEARCH
Volume 10, Issue 1, Pages 331S-336SPublisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-031212
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [P50CA058183, P01CA030195] Funding Source: NIH RePORTER
- NCI NIH HHS [P50 CA58183, P01 CA30195] Funding Source: Medline
Ask authors/readers for more resources
Introduced more than 100 years ago, endocrine therapy is still the most important systemic therapy for all stages of estrogen receptor (ER) -positive breast tumors. A major clinical problem limiting the usefulness of this therapy is tumor resistance, either de novo or acquired during the course of the treatment. Relatively new discoveries emphasize the complexity of ER signaling and its multiple regulatory interactions with growth factor and other kinase signaling pathways. Both genomic (nuclear) and nongenomic (membrane and cytoplasmic) ER activities contribute to this intimate cross-talk, which is probably a fundamental factor in endocrine resistance. New targeted therapies, especially against the epidermal growth factor receptor/HER-2 pathway, should be carefully evaluated in more (bio)logical strategies to enable them to be exploited appropriately. A strategy of combining endocrine therapy (particularly tamoxifen) with these inhibitors, to circumvent de novo and acquired resistance, will be discussed. We will also emphasize open questions and future challenges in the dynamic research field of molecular ER biology from the endocrine therapy perspective.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available